You are here

  • Home
  • Archive
  • Volume 10, Issue 5
  • CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

Article metrics

Article menu

This article has a correction. Please see:

Clinical/translational cancer immunotherapy
Original research
CD4+ T-cell epitope-based heterologous prime-boost vaccination potentiates anti-tumor immunity and PD-1/PD-L1 immunotherapy

 

Online download statistics by month:

Online download statistics by month: May 2022 to March 2024

AbstractFullPdf
May 2022480483247
Jun 2022400409197
Jul 2022246255101
Aug 2022274284135
Sep 202225926271
Oct 2022333340118
Nov 2022252253126
Dec 2022159165103
Jan 202315515782
Feb 2023178183123
Mar 2023212212125
Apr 2023182182109
May 202314614787
Jun 202310310678
Jul 202311711786
Aug 202312112479
Sep 202311711769
Oct 2023166166130
Nov 2023162162101
Dec 2023151153140
Jan 2024152153127
Feb 2024125127101
Mar 2024204208198
Total469447652733